July 19, 2018

July 17, 2018

July 17, 2018

July 16, 2018 – Author, Les Masterson

Dive Brief:

• Executive and clinician respondents to a new NEJM Catalyst survey said knowing out-of-pocket costs is important to patients and more than 60% said physicians are responsible for educating patients about these costs. However, nearly half don’t think physicians should be held accountable for those costs.
• Slightly more than three-fourths of respondents said their organizations consider the cost to the practice and system when making clinical decisions. A slightly lower number (72%) said they consider patient out-of-pocket costs, while 68% said they think about the total cost of care.
• Respondents said the stakeholders that have the biggest impact on healthcare costs are pharmaceutical/biotech companies (87%), health plans (81%) and hospitals/health systems/physician organizations (75%). Only 28% pointed the finger at individual clinicians and even fewer blamed employers (26%) and patients (23%).

Dive Insight:

These results show that thought leaders believe physicians should play a role, but shouldn’t be penalized for the actual cost of care. Plus, other healthcare stakeholders are encouraged to improve processes and tools to better educate patients on costs.

The findings come as more payers are pushing providers into value-based contracting. The different payment method incentivizes and penalizes physicians and health systems to keep costs under control and provide a minimum level of care quality. The concept behind value-based payment does include holding doctors accountable for costs to an extent.

 

READ THE REST HERE

 

JUL 16, 2018 – Jeff Lagasse, Associate Editor

There’s a lot of work involved in making the transition from fee-for-service payment models to performance-based arrangements. Changes are needed to outdated delivery models, there needs to be more responsibility for care coordination, and providers are tasked with finding ways to gain a competitive advantage in the market.

Jeff Smith, senior vice president and head of U.S. markets at Lumeris, said addressing these issues positions health systems to solve the dilemma created by the industry’s long-standing structural separation of care delivery — its costs, reimbursement, and quality — by integrating actionable intelligence, information, workflows incentives and tools.

This, he said, creates a new paradigm of behaviors that drives better clinical outcomes, lowers cost and creates superior engagement and satisfaction among providers and consumers.

It’s an issue that Lumeris and Cerner are attempting to tackle with a new partnership that has created Maestro Advantage, which combines the technology of both companies and allows providers to streamline redundant services — a nagging problem in the volume-to-value shift.

These redundant services include “lengthy claims processing and reimbursement cycles, and obstacles to sharing data and records,” Smith said. “Healthcare must continue to shift its focus from a system focused on sick care to well care — a system that promotes health and wellness. The transition to value-based care is a long journey.”

The shift to value creates other challenges as well. Increasingly, providers are determining physician pay through a number of different means. The options include straight salary, compensation based on personal productivity (as has been the case in a fee-for-service world), bonus structures and tying pay to an organization’s overall financial performance.

 

READ THE REST HERE

 

WESTMINSTER, Colo., July 13, 2018 /PRNewswire/ — Cerapedics, a privately-held orthobiologics company, today announced that the company completed a $22 million financing led by KCK Group, a family investment fund that focuses on innovative medical technologies that meet significant clinical needs.

“We are pleased to announce that we have successfully completed an equity financing that will continue to accelerate the commercial release of i-FACTOR™ Peptide Enhanced Bone Graft and support the execution of a second Level I investigational device exemption (IDE) human clinical study that will broaden our market indication in the $2 billion U.S. spinal market,” said Glen A. Kashuba, chief executive officer of Cerapedics. “This year we have exceeded our own expectations regarding year over year revenue growth and have significantly expanded our user base as surgeons continue to express a high level of satisfaction with clinical results that support the safety and efficacy of our product. We also understand the value of Level I human clinical data and are committed to investing and expanding our indications. We are fortunate to be supported by KCK Group, a partner that shares in the long-term vision that differentiated products that provide safety, efficacy and economic value, supported by human clinical results, will ultimately provide the highest value to surgeons and their patients.”

Cerapedics also announced that three new members have been appointed to the company’s board of directors including Valeska Schroeder, Ph.D., managing director of the medical technologies division at KCK Group, Greg Garfield, J.D., senior managing director and head of the medical technologies division at KCK Group, and Nael Karim Kassar, investment partner at KCK Group.

“Cerapedics is well-positioned for strong growth with Level I data establishing i-FACTOR’s superiority and with a dedicated team that has deep experience in orthobiologics and spinal fusion,” said Dr. Schroeder. “This financing will allow Cerapedics to further invest to increase physician access to i-FACTOR and to build clinical evidence for new indications.”

i‑FACTOR Peptide Enhanced Bone Graft is based on proprietary biomimetic small peptide (P-15) technology that has a novel mechanism of action (attract, attach, and activate) that induces osteoblast cell proliferation and differentiation to accelerate new bone formation in patients with degenerative disc disease. This unique drug-device technology enhances the body’s natural bone healing process through cellular activity that is directional and predictable.

Cerapedics received Premarket Approval (PMA) from the U.S. Food & Drug Administration for the use of i-FACTOR Peptide Enhanced Bone Graft in anterior cervical discectomy and fusion (ACDF) procedures, becoming the first PMA-approved bone graft with this indication. The company has also initiated an IDE clinical trial in transforaminal lumbar interbody fusion (TLIF) surgery.

About Cerapedics

Cerapedics is an orthobiologics company focused on developing and commercializing its proprietary biomimetic small peptide (P-15) technology platform. i‑FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors. More information can be found at www.cerapedics.com.

i‑FACTOR Peptide Enhanced Bone Graft Indications for Use

USA: i‑FACTOR Peptide Enhanced Bone Graft is indicated for use in skeletally mature patients for reconstruction of a degenerated cervical disc at one level from C3-C4 to C6-C7 following single-level discectomy for intractable radiculopathy (arm pain and/or a neurological deficit), with or without neck pain, or myelopathy due to a single-level abnormality localized to the disc space, and corresponding to at least one of the following conditions confirmed by radiographic imaging (CT, MRI, X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), and/or visible loss of disc height as compared to adjacent levels, after failure of at least 6 weeks of conservative treatment. i‑FACTOR Peptide Enhanced Bone Graft must be used inside an allograft bone ring and with supplemental anterior plate fixation.

Media contact: 

Jenna Iacurci

Berry & Company Public Relations 

212-253-8881 

jiacurci@berrypr.com

SOURCE Cerapedics

Related Links

http://www.cerapedics.com

Press Release – July 13, 2018

Artoss, Inc. is pleased to announce the successful completion of its recent funding round of Unsecured Convertible Notes. The round, which began in 2017 with a target of raising $500,000, was oversubscribed to twice that amount or a total of $1 million.

James J. Cassidy, Ph.D., Managing Director of Artoss, Inc., the exclusive North American distributors for NanoBone® Bone Graft in orthopaedic surgery, said, “We have been overwhelmed by the interest shown in our second round of angel funding. We are especially grateful to those investors who participated in our 2016 funding round and chose to increase their investment in this round as well as to our new investors for their support of Artoss.”

Paul Byerley, Managing Director of Artoss, Inc. said, “We are very pleased with our commercial success to-date and appreciate the support of our investors. Surgeon feedback on the clinical performance of NanoBone SBX Putty and QD remains extremely positive. We look forward to expanding our distribution network to put our superior bone grafting solution in the hands of more surgeons.”

Artoss, Inc. is using the proceeds of this funding to support the development of additional NanoBone Bone Graft products for the US market, for costs associated with regulatory requirements, and for commercialization activities.

 

For further information, please contact:

Artoss, Inc.

425 E Saint Germain St., Suite 106

Saint Cloud, MN 56304-0752

320-259-4321

info@artossinc.com

 

Ecully, 11 July 2018

Revenue for the first half of 2018

07-12-2018 – Press Release from: Market Research Future

Market Research Future has a half cooked research report about Global Spinal Implants Market which is currently growing tremendously and is expected to reach USD of 14 billion by the end of 2022.

The Global Spinal Implants Market has been evaluated to be rapidly growing market and is expected to grow tremendously in the near future. Spinal implants are devices used by surgeons during surgery to treats deformities, stabilizes and provides strength to the spine and to expedite the fusion process. Spinal implants are used to treat spine related disorders including degenerative disc disease, scoliosis, kyphosis, fracture and spondylolisthesis.

As age increases bone density declines which leads to chronic back problems which is common in old age people. This elevates spinal cord damage risk. Recently there have been amazing innovations in implantable devices allowing enhancement of the same the result of which is their use have increased in spinal and orthopedic surgeries. Advanced spinal implantable devices are widely accepted globally as maximum people are willing to spend on spinal surgeries which includes use of these devices. The demand for minimally invasive surgical procedures is more as it provides benefits like less blood loss, less recovery time, reduce risk of medical complication, infections, pain and muscle damage. Minimally invasive spinal surgeries are done more which has boosted the market of spinal implants.

Get Sample PDF Illustration @ www.marketresearchfuture.com/sample_request/2050

There are some other factors which have substantial impact on the spinal implant market. Rise in number of vehicular accidents, increased spinal injuries and disorders, increasing geriatric and obese population, lack of proper nutrition and exercise which are consequently increasing chronic back problems. All these are some of the factors which are responsible for the growth of the global spinal implants market. However, high cost of the spinal implants, spinal surgical procedures and unstable reimbursement policies put immense pressure on developing nations and the low income economies causing hindrance to the growth of the spinal implants market.

Key Players for Global Spinal Implants Market

Some major players in the Global Spinal Implants Market include Medtronic, plc (Ireland), Depuy Synthes Inc. (Johnson & Johnson) (U.S.), Stryker Corporation (U.S.), NuVasive, Inc. (U.S.), Zimmer Biomet Holdings, Inc. (U.S.), Globus Medical, Inc. (U.S.), Alphatec Holdings, Inc. (U.S.), Orthofix International N.V. (Netherlands), K2M Group Holdings, Inc. (U.S.), RTI Surgical, Inc. (U.S.), Amedica Corporation (U.S.), Exactech Inc. (U.S.), Integra LifeSciences (U.S.), LDR Holding Corporation (U.S.), Quandary Medical LLC (U.S.), AESCULAP (U.S.), Alliance Spine (U.S.), Apollo Spine (U.S.), Premia Spine (Israel), Ascendx Spine (U.S.), A-Spine (Taiwan), Back 2 Basics Spine (Canada), Accel Spine (U.S.), SI-BONE (U.S.), Captiva Spine Inc. (U.S.), Centinel Spine (U.S.), Life Spine (U.S.), SpineGuard (France), NLT Spine (U.S.), Paradigm Spine LLC (U.S.), Precision Spine (U.S.), Reliance Medical Systems (U.S.), Spinal Solutions Inc. (U.S.), Spine Frontier (U.S.), Spineart Geneva SA (Switzerland), and others

Segments for Global Spinal Implants Market

The Global Spinal Implants Market consists of four regions, namely, America, Europe, Asia Pacific, and the Middle East and Africa.

Americas dominated the global spinal implants market owing to the technological innovation, advancement in manufacturing processes, and contribution of nanotechnology to the pharmaceutical packaging market.

Get Prime Discount on Report @ www.marketresearchfuture.com/check-discount/2050

The European region is the second largest market owing to the increase in geriatric population and the increasing demand for spinal implants and devices for the treatment of spinal disorders. Asia Pacific is the emerging market in the global spinal implants market owing to the rising obesity cases, increasing healthcare expenditure in developing nations, increasing government funding, the presence of a large patient population, and growing awareness about novel spine treatment techniques.

Some Brief Table of Contents of Report

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

TOC Continued…

Do You Have Specific Requirement? Ask To Our Experts@ www.marketresearchfuture.com/enquiry/2050

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Market Research Future

Hadapsar, Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.

SAN DIEGO, July 11, 2018 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the Company will release its second quarter 2018 earnings results on Tuesday, July 31, 2018 after the close of the market.

NuVasive will hold a conference call on Tuesday, July 31, 2018 at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the second quarter 2018. The dial-in numbers are 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers. A live webcast of the conference call will be available online from the Investor Relations page of the Company’s website at www.nuvasive.com.

After the live webcast, the call will remain available on NuVasive’s website through August 28, 2018. In addition, a telephone replay of the call will be available until August 7, 2018. The replay dial-in numbers are 1-844-512-2921 for domestic callers and 1-412-317-6671 for international callers. Please use pin number: 13681479.

About NuVasive

NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally-integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company’s portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400 person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.nuvasive.com.

Forward-Looking Statements

NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, but are not limited to, the risk that NuVasive’s revenue or earnings projections may turn out to be inaccurate because of the preliminary nature of the forecasts; the risk of further adjustment to financial results or future financial expectations; unanticipated difficulty in selling products, generating revenue or producing expected profitability; and those other risks and uncertainties more fully described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

SOURCE NuVasive, Inc.

Related Links

http://www.nuvasive.com